Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05986292
Other study ID # 17511
Secondary ID H0P-MC-CPMP
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 30, 2020
Est. completion date April 25, 2027

Study information

Verified date May 2024
Source Eli Lilly and Company
Contact There may be multiple sites in this clinical trial. 1-877-CTLILL
Phone 1-317-615-4559
Email ClinicalTrials.gov@lilly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.


Description:

The chronic pain master protocol (CPMP) establishes entry criteria and includes DSA for osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. The DSA have specific study elements to appropriately define the target population and unique scales for assessment. Also, the master protocol governs ISAs that may start independently of other ISAs as interventions become available for clinical testing. Note: Results for all outcomes are posted in the intervention records. No need for duplication.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date April 25, 2027
Est. primary completion date April 25, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - have a visual analog scale (VAS) pain value >40 and <95 at screening and prerandomization screening. - have a history of daily pain for at least 12 weeks based on participant report or medical history - have a value of =30 on the pain catastrophizing scale - have a body mass index <40 kilogram/square meter (kg/m²) (inclusive) - are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation. - are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study Exclusion Criteria: - have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia - have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques) - have surgery planned during the study for any reason, related or not to the disease state under evaluation. - have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation. - have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision. - have fibromyalgia - have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association) - have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study. - have a positive human immunodeficiency virus (HIV) test result at screening - have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.

Study Design


Intervention

Drug:
LY3016859 ISA
Administered intravenously (IV)
LY3556050 ISA
Administered orally
LY3526318 ISA
Administered orally
LY3857210 ISA
Administered orally
Placebo Oral
Placebo administered orally
Placebo
Placebo administered IV

Locations

Country Name City State
Puerto Rico Ponce Medical School Foundation Inc. Ponce
Puerto Rico Latin Clinical Trial Center San Juan
United States FutureSearch Trials of Neurology Austin Texas
United States VIN-Julie Schwartzbard Aventura Florida
United States Great Lakes Research Group, Inc. Bay City Michigan
United States Northwest Clinical Research Center Bellevue Washington
United States Simon Williamson Clinic Birmingham Alabama
United States Northwestern University Chicago Illinois
United States Synexus Clinical Research Chicago Illinois
United States Synexus - Cincinnati Cincinnati Ohio
United States Aventiv Research Inc Columbus Ohio
United States Cedar Health Research Dallas Texas
United States Synexus Dallas Texas
United States META Medical Research Institute Dayton Ohio
United States Accel Research Sites- Clinical Research Unit DeLand Florida
United States Altoona Center For Clinical Research Duncansville Pennsylvania
United States Lillestol Research Fargo North Dakota
United States Synexus Clinical Research - Glendale Glendale Arizona
United States PharmQuest Greensboro North Carolina
United States CMR of Greater New Haven, LLC Hamden Connecticut
United States Irvine Clinical Research Irvine California
United States Encore Research Group- Jacksonville Center for Clinical Research Jacksonville Florida
United States ActivMed Practices and Research Methuen Massachusetts
United States New Horizon Research Center Miami Florida
United States Suncoast Research Group Miami Florida
United States SYNEXUS Murray Utah
United States DelRicht Research New Orleans Louisiana
United States Coastal Carolina Research Center North Charleston South Carolina
United States Renstar Medical Research Ocala Florida
United States Synexus Clinical Research US, Inc. Omaha Nebraska
United States Desert Oasis Healthcare Medical Group Palm Springs California
United States Arizona Research Center Phoenix Arizona
United States Central Phoenix Medical Clinic Phoenix Arizona
United States Synexus Clinical Research - St. Petersburg Pinellas Park Florida
United States Martin E. Hale M.D., P.A. Plantation Florida
United States Rainier Clinical Research Center Renton Washington
United States Artemis Institute for Clinical Research Riverside California
United States Rochester Clinical Research, LLC Rochester New York
United States StudyMetrix Research Saint Peters Missouri
United States Synexus Clinical Research US, Inc. San Antonio Texas
United States Artemis Institute for Clinical Research San Diego California
United States Clinvest Research LLC Springfield Missouri
United States Alliance for Multispecialty Research, LLC Tempe Arizona
United States Synexus Clinical Research US, Inc. The Villages Florida
United States Cotton O'Neil Clinical Research Center - Central Office Topeka Kansas
United States DelRicht Research Tulsa Oklahoma
United States MedVadis Research Corporation Waltham Massachusetts
United States North Georgia Clinical Research Woodstock Georgia
United States Clinical Research Center of Reading,LLC Wyomissing Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Were Allocated to Each ISA Baseline, Up to Week 8
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Completed NCT02901964 - Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial N/A
Completed NCT02905747 - The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis N/A
Not yet recruiting NCT02865174 - Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty Phase 4